VaxGen smallpox vaccine doubles survival time in animal study

By Elaine Rigoli

Tampa, Fla., June 6 - VaxGen, Inc. said new non-clinical data from a study of the company's attenuated smallpox vaccine candidate, LC16m8, showed that all Dryvax-inoculated animals died within seven days after intrathalamic inoculation.

In contrast, VaxGen said all animals that received LC16m8 survived for the duration of the 15-day study.

VaxGen said it is developing LC16m8 for use in the United States and elsewhere in partnership with the Chemo-Sero-Therapeutic Research Institute of Kumamoto, Japan, the licensed manufacturer of LC16m8.

VaxGen, located in South San Francisco, Calif., is a biopharmaceutical company engaged in the development of biologic products for the prevention and treatment of human infectious diseases, including anthrax and smallpox.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.